Business / Finance

RSS
Prairie Technologies acquired by Bruker

Prairie Technologies acquired by Bruker

Cell Therapeutics agrees to sell 15,000 shares of Series 18 Preferred Stock to Quogue Capital

Cell Therapeutics agrees to sell 15,000 shares of Series 18 Preferred Stock to Quogue Capital

Global Industry Analysis Report on Companion Diagnostics Market

Global Industry Analysis Report on Companion Diagnostics Market

Craneware announces financial results for fiscal year 2013

Craneware announces financial results for fiscal year 2013

Euclid Systems, Wenzhou Medical University Eye Hospital sign cooperation agreement

Euclid Systems, Wenzhou Medical University Eye Hospital sign cooperation agreement

Breckenridge acquires Cypress Pharmaceutical product assets from Pernix Therapeutics

Breckenridge acquires Cypress Pharmaceutical product assets from Pernix Therapeutics

Elsevier collaborates with EI in organizing first Energy Systems conference to be held on June 2014, London

Elsevier collaborates with EI in organizing first Energy Systems conference to be held on June 2014, London

MJFF awards $1.35M to Rhythm for Phase 2 clinical trial of RM-131 for Parkinson's disease

MJFF awards $1.35M to Rhythm for Phase 2 clinical trial of RM-131 for Parkinson's disease

Power Balance Technologies joins NBCF with the new 'Breast Cancer Awareness' Wristband

Power Balance Technologies joins NBCF with the new 'Breast Cancer Awareness' Wristband

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.